Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...

Our viewpoint is that in cases of ultra rare diseases where there is no commercial model or opportunity for traditional forms of investment, access to gene therapies could be provided via a clinical ...